Ultragenyx Receivables Turnover from 2010 to 2024

RARE Stock  USD 47.24  1.22  2.65%   
Ultragenyx's Receivables Turnover is increasing over the years with slightly volatile fluctuation. Receivables Turnover is expected to dwindle to 5.34. During the period from 2010 to 2024 Ultragenyx Receivables Turnover annual values regression line had geometric mean of  1.67 and mean square error of  8.94. View All Fundamentals
 
Receivables Turnover  
First Reported
2010-12-31
Previous Quarter
5.91700504
Current Value
5.34
Quarterly Volatility
4.28588398
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Ultragenyx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ultragenyx's main balance sheet or income statement drivers, such as Depreciation And Amortization of 27.3 M, Interest Expense of 69.3 M or Selling General Administrative of 325.3 M, as well as many indicators such as Price To Sales Ratio of 7.69, Dividend Yield of 0.0028 or PTB Ratio of 16.58. Ultragenyx financial statements analysis is a perfect complement when working with Ultragenyx Valuation or Volatility modules.
  
Check out the analysis of Ultragenyx Correlation against competitors.
For information on how to trade Ultragenyx Stock refer to our How to Trade Ultragenyx Stock guide.

Latest Ultragenyx's Receivables Turnover Growth Pattern

Below is the plot of the Receivables Turnover of Ultragenyx over the last few years. It is Ultragenyx's Receivables Turnover historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ultragenyx's overall financial position and show how it may be relating to other accounts over time.
Receivables Turnover10 Years Trend
Slightly volatile
   Receivables Turnover   
       Timeline  

Ultragenyx Receivables Turnover Regression Statistics

Arithmetic Mean3.71
Geometric Mean1.67
Coefficient Of Variation115.68
Mean Deviation3.49
Median0.51
Standard Deviation4.29
Sample Variance18.37
Range11.8545
R-Value0.74
Mean Square Error8.94
R-Squared0.55
Significance0
Slope0.71
Total Sum of Squares257.16

Ultragenyx Receivables Turnover History

2024 5.34
2023 5.92
2022 8.98
2021 12.36
2020 11.74
2019 3.16
2018 4.04

About Ultragenyx Financial Statements

Ultragenyx stakeholders use historical fundamental indicators, such as Ultragenyx's Receivables Turnover, to determine how well the company is positioned to perform in the future. Although Ultragenyx investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ultragenyx's assets and liabilities are reflected in the revenues and expenses on Ultragenyx's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ultragenyx. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Receivables Turnover 5.92  5.34 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Ultragenyx is a strong investment it is important to analyze Ultragenyx's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ultragenyx's future performance. For an informed investment choice regarding Ultragenyx Stock, refer to the following important reports:
Check out the analysis of Ultragenyx Correlation against competitors.
For information on how to trade Ultragenyx Stock refer to our How to Trade Ultragenyx Stock guide.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ultragenyx. If investors know Ultragenyx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ultragenyx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.35)
Revenue Per Share
6.015
Quarterly Revenue Growth
0.423
Return On Assets
(0.24)
Return On Equity
(2.90)
The market value of Ultragenyx is measured differently than its book value, which is the value of Ultragenyx that is recorded on the company's balance sheet. Investors also form their own opinion of Ultragenyx's value that differs from its market value or its book value, called intrinsic value, which is Ultragenyx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ultragenyx's market value can be influenced by many factors that don't directly affect Ultragenyx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ultragenyx's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ultragenyx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ultragenyx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.